HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
Graduate School of Medicine / Faculty of Medicine >
Peer-reviewed Journal Articles, etc >

Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation : An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)

This item is licensed under: Creative Commons Attribution-NonCommercial 4.0 International

Files in This Item:

The file(s) associated with this item can be obtained from the following URL:https://doi.org/10.1111/dom.13879


Title: Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation : An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)
Authors: Cho, Kyu Yong Browse this author
Nomoto, Hiroshi Browse this author
Nakamura, Akinobu Browse this author →KAKEN DB
Kawata, Shinichiro Browse this author
Sugawara, Hajime Browse this author
Takeuchi, Jun Browse this author
Nagai, So Browse this author
Tsuchida, Kazuhisa Browse this author
Omori, Kazuno Browse this author
Yokoyama, Hiroki Browse this author
Manda, Naoki Browse this author
Kurihara, Yoshio Browse this author
Aoki, Shin Browse this author
Atsumi, Tatsuya Browse this author →KAKEN DB
Miyoshi, Hideaki Browse this author →KAKEN DB
Keywords: continuous glucose monitoring
DPP-4 inhibitor
randomized trial
SGLT2 inhibitor
type 2 diabetes
Issue Date: Mar-2020
Publisher: John Wiley & Sons
Journal Title: Diabetes, Obesity and Metabolism
Volume: 22
Issue: 3
Start Page: 458
End Page: 462
Publisher DOI: 10.1111/dom.13879
Abstract: This multicentre, prospective, randomized, open-label, blinded-endpoint, parallel-group, short-term (4-5 weeks) controlled trial was conducted to investigate the superiority of the effect of reducing mean amplitude of glycaemic excursions (MAGE) during meal tolerance tests (MTTs) for the combination of dipeptidyl peptidase-4 (DPP-4) inhibitor and sodium-glucose co-transporter-2 (SGLT2) inhibitor compared with SGLT2 inhibitor monotherapy. Ninety-nine patients with type 2 diabetes who were taking teneligliptin (20 mg/d) were randomized to one of the following two groups: those who switched to 100 mg/d of canagliflozin (SWITCH group) or those who added 100 mg/d of canagliflozin (COMB group). MAGE in the COMB group was significantly decreased compared with that in the SWITCH group (COMB 117.5 +/- 39.8 to 92.2 +/- 28.0 mg/dL vs SWITCH 110.7 +/- 29.8 to 104.2 +/- 27.6 mg/dL; P<0.01). Mean blood glucose decreased significantly during MTTs in both groups, although the extent of the reduction was significantly greater in the COMB group (COMB 142.3 +/- 28.7 to 119.5 +/- 25.1 mg/dL vs SWITCH 146.4 +/- 25.5 to 135.5 +/- 22.4 mg/dL; P < 0.01). SGLT2 inhibitor combined with DPP-4 inhibitor therapy strongly reduced glycaemic fluctuation compared with SGLT2 inhibitor monotherapy.
Rights: https://creativecommons.org/licenses/by-nc/4.0/
Type: article
URI: http://hdl.handle.net/2115/76814
Appears in Collections:医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

Export metadata:

OAI-PMH ( junii2 , jpcoar )

MathJax is now OFF:


 

 - Hokkaido University